Clinical Scorecard: Plasma Proteomics and Insulin Sensitivity in Relation to Sex Hormone Treatment
At a Glance
Category
Detail
Condition
Insulin resistance and sensitivity influenced by sex hormone therapy
Key Mechanisms
Sex hormones (estradiol and testosterone) modulate insulin sensitivity via molecular pathways involving immunoregulation, inflammation, iron homeostasis, erythropoiesis, and oxidative stress
Target Population
Transgender individuals initiating feminizing or masculinizing hormone therapy aged 17-40 years without diabetes or cardiovascular disease
Care Setting
Specialized gender-affirming hormone therapy clinics and research centers
Key Highlights
Feminizing hormone therapy (estradiol with GnRH analogue) increased insulin sensitivity by approximately 20-23% after 3 months.
Masculinizing hormone therapy (testosterone) did not significantly change insulin sensitivity over the same period.
Proteomic analysis identified 16 plasma proteins correlated with insulin sensitivity changes, involving pathways of inflammation, iron metabolism, and oxidative stress.
Guideline-Based Recommendations
Diagnosis
Use hyperinsulinemic-euglycemic clamp as the gold-standard method to assess insulin sensitivity in clinical research settings.
Avoid reliance solely on surrogate measures like HOMA-IR for whole-body insulin sensitivity, especially in small trials or transgender populations.
Management
Consider feminizing hormone therapy with estradiol and GnRH analogues to improve insulin sensitivity in transgender women.
Avoid cyproterone acetate in feminizing regimens when assessing metabolic effects due to its potential to worsen insulin resistance.
Monitor testosterone therapy effects carefully in transgender men as it may not improve insulin sensitivity.
Monitoring & Follow-up
Assess insulin sensitivity before and after initiation of sex hormone therapy to evaluate metabolic impact.
Monitor plasma proteomic markers related to immunoregulation, iron homeostasis, and oxidative stress to understand molecular changes.
Risks
Potential confounding effects of antiandrogens like cyproterone acetate on insulin sensitivity.
Elevated testosterone in postmenopausal women may decrease insulin sensitivity; effects may differ by sex and hormone status.
Patient & Prescribing Data
Transgender individuals aged 17-40 initiating hormone therapy without prior hormone use or significant comorbidities.
Feminizing hormone therapy with estradiol and GnRH analogues enhances insulin sensitivity, while masculinizing therapy with testosterone shows no significant change after 3 months.
Clinical Best Practices
Use gold-standard clamp techniques to measure insulin sensitivity in clinical studies involving sex hormone therapy.
Prefer GnRH analogues over cyproterone acetate in feminizing hormone regimens to avoid confounding metabolic effects.
Integrate plasma proteomics to identify molecular pathways affected by hormone therapy and guide precision medicine approaches.
Screen and exclude patients with diabetes, cardiovascular disease, or kidney disease to isolate hormone therapy effects on insulin sensitivity.
Obtain ethical approvals and informed consent when conducting hormone therapy research.
by Sarah A van Eeghen, Laura Pyle, Phoom Narongkiatikhun, Ye Ji Choi, Taryn G Vosters, Irene G M van Valkengoed, Petter Bjornstad, Sarah E Siegelaar, Natalie J Nokoff, Martin den Heijer, Daniël H van Raalte
